Singapore, July 2 -- WuXi XDC Cayman Inc. a leading global Contract Research, Development and Manufacturing Organisation (CRDMO) focused on the bioconjugate industry, has announced that the mechanical completion of its manufacturing site atTuas Biomedical Park inSingaporehas been successfully achieved.

This milestone signifies that this manufacturing site, spanning approximately 25,000 square meters, will now officially transition into the facility C&Q (Commissioning and Qualification) stage. TheSingaporesite is expected to commence operations by the end of 2025 and Good Manufacturing Practice (GMP) manufacturing in 2026. Upon that, the site will offer comprehensive production capabilities from the preclinical stage to commercialisation....